P Madhivanan1, K Krupp2, M Coudray3, B Colbert4, D Ruiz-Perez5, H Cui6, N Bokulich7, G Narasimhan8, K Mathee9, R L Cook10, J Schwebke11, D Roe12. 1. Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA; College of Medicine, University of Arizona, Tucson, USA; University of Arizona Comprehensive Cancer Center, Tucson, USA. Electronic address: pmadhivanan@arizona.edu. 2. Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA; University of Arizona Comprehensive Cancer Center, Tucson, USA. Electronic address: kkrupp@arizona.edu. 3. Robert Stempel College of Public Health and Social Work, Florida International University, Miami, USA; College of Medicine, University of Central Florida, Orlando, USA. Electronic address: Makella.Coudray@ucf.edu. 4. Herbert Wertheim College of Medicine, Florida International University, Miami, USA. Electronic address: bmc48@miami.edu. 5. Bioinformatic Research Group (BioRG), School of Computing and Information Sciences, Florida International University, Miami, USA. Electronic address: druiz072@cs.fiu.edu. 6. University of Arizona Comprehensive Cancer Center, Tucson, USA. Electronic address: HCui@uacc.arizona.edu. 7. Laboratory of Food Systems Biotechnology, Institute of Food, Nutrition and Health, ETH Zurich, Switzerland. Electronic address: Nicholas.Bokulich@hest.ethz.ch. 8. Herbert Wertheim College of Medicine, Florida International University, Miami, USA. Electronic address: giri@cs.fiu.edu. 9. Herbert Wertheim College of Medicine, Florida International University, Miami, USA. Electronic address: matheek@fiu.edu. 10. College of Public Health and Health Professions, University of Florida, Gainesville, USA. Electronic address: cookrl@ufl.edu. 11. College of Medicine, University of Birmingham, Alabama, USA. Electronic address: janeschwebke@gmail.com. 12. Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA; University of Arizona Comprehensive Cancer Center, Tucson, USA. Electronic address: droe@arizona.edu.
Abstract
BACKGROUND: Chronic infection with high-risk human papillomavirus is a necessary cause for cervical carcinogenesis. This study examined prevalence of nonavalent vaccine preventable HPV types over four months among sexually active women in the United States. METHODS: This sub-study obtained meta-data for 80 of the 1,365 women (18-25 years), enrolled in the BRAVO study, a randomized, open-label trial of home screening and treatment of asymptomatic bacterial vaginosis at high-risk for sexually transmitted infections conducted between 2008 and 2013. Participants were randomized to treatment or standard-of-care, and followed every 2-months for 12 months. Stored vaginal swabs from the first three visits were tested for the nine vaccine preventable HPV types using quantitative PCR. Prevalence and associated 95% confidence intervals for the HPV types were assessed using R (version 3.6.1). RESULTS: The average age of the participants was 21.5 (SD ± 2.11) years, with 60% having ever been pregnant and all were African-American. Majority (71%) reported ≥ two sex partners in the prior year with 89% having unprotected vaginal sex and 45% having a new sex partner in the prior year. About 30% had ≥ one of the nine nonavalent vaccine HPV types at all three time points over a period of four months, 15% at two of any three visits, 19% at one of the three visits and 36% were negative for all nine vaccine HPV types at all time points. The most frequently detected HPV vaccine types were 52, 58, 16, and 18. The prevalence of any vaccine HPV types, and high-risk HPV types was 63.8% and 58.8%, respectively. CONCLUSIONS: Our findings suggest that HPV vaccination which is currently recommended for all unvaccinated persons through age 26 years, is likely to be more beneficial than previously thought as nonavalent HPV vaccine was not available during the time these data were collected.
BACKGROUND: Chronic infection with high-risk human papillomavirus is a necessary cause for cervical carcinogenesis. This study examined prevalence of nonavalent vaccine preventable HPV types over four months among sexually active women in the United States. METHODS: This sub-study obtained meta-data for 80 of the 1,365 women (18-25 years), enrolled in the BRAVO study, a randomized, open-label trial of home screening and treatment of asymptomatic bacterial vaginosis at high-risk for sexually transmitted infections conducted between 2008 and 2013. Participants were randomized to treatment or standard-of-care, and followed every 2-months for 12 months. Stored vaginal swabs from the first three visits were tested for the nine vaccine preventable HPV types using quantitative PCR. Prevalence and associated 95% confidence intervals for the HPV types were assessed using R (version 3.6.1). RESULTS: The average age of the participants was 21.5 (SD ± 2.11) years, with 60% having ever been pregnant and all were African-American. Majority (71%) reported ≥ two sex partners in the prior year with 89% having unprotected vaginal sex and 45% having a new sex partner in the prior year. About 30% had ≥ one of the nine nonavalent vaccine HPV types at all three time points over a period of four months, 15% at two of any three visits, 19% at one of the three visits and 36% were negative for all nine vaccine HPV types at all time points. The most frequently detected HPV vaccine types were 52, 58, 16, and 18. The prevalence of any vaccine HPV types, and high-risk HPV types was 63.8% and 58.8%, respectively. CONCLUSIONS: Our findings suggest that HPV vaccination which is currently recommended for all unvaccinated persons through age 26 years, is likely to be more beneficial than previously thought as nonavalent HPV vaccine was not available during the time these data were collected.
Authors: Helen Kelly; Helena Faust; Admire Chikandiwa; Jean Ngou; Helen A Weiss; Michel Segondy; Joakim Dillner; Sinead Delany-Moretlwe; Philippe Mayaud Journal: J Infect Dis Date: 2018-08-14 Impact factor: 5.226
Authors: Rebecca B Perkins; Jack A Clark; Gauri Apte; Jessica L Vercruysse; Justen J Sumner; Constance L Wall-Haas; Anna W Rosenquist; Natalie Pierre-Joseph Journal: Pediatrics Date: 2014-09 Impact factor: 7.124
Authors: Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Jane R Schwebke; Jeannette Y Lee; Shelly Lensing; Susan S Philip; Harold C Wiesenfeld; Arlene C Seña; Nikole Trainor; Nincoshka Acevado; Lisa Saylor; Ann M Rompalo; Robert L Cook Journal: Clin Infect Dis Date: 2015-11-26 Impact factor: 9.079